Serapha Bio has reported encouraging early clinical results for SERP-01, an investigational one-time gene-editing treatment for alpha-1 antitrypsin deficiency, showing that all four treated patients achieved circulating protein levels above a proposed protective threshold. The investigator-initiated study also demonstrated sustained biochemical activity for up to 10 months and 54% correction of the targeted disease-causing genetic mutation in a liver biopsy from one participant. The findings provide preliminary human evidence that in vivo base editing could address the underlying genetic defect responsible for a serious inherited condition affecting the lungs and liver.
The results, presented at the European Respiratory Society Alpha-1 Antitrypsin Conference 2026, support Serapha Bio’s preparations for a U.S. Phase 2/3 clinical trial in late 2026 or early 2027. However, the four-patient study remains exploratory, and longer follow-up is required to establish whether the observed molecular changes translate into sustained protection against organ damage.
How did SERP-01 perform in the first four patients with severe alpha-1 antitrypsin deficiency?
The ongoing investigator-initiated clinical study is evaluating YOLT-202, known as SERP-01 under Serapha Bio’s development program, in patients carrying the PiZZ genotype associated with severe alpha-1 antitrypsin deficiency. The study is being conducted through a collaboration involving Renji Hospital in Shanghai and Hannover Medical School in Germany. Investigators administered a single intravenous infusion to four participants, with one receiving 35 mg and three receiving 45 mg.
As of the October 15 data cutoff, all four patients demonstrated rapid, dose-dependent increases in total circulating alpha-1 antitrypsin above the proposed protective threshold of 11 micromoles per liter. Among participants receiving 45 mg, total protein concentrations were at or near the lower limit of the normal range, approximately 20 micromoles per liter, during available follow-up extending to 10 months.
These results are important because severe alpha-1 antitrypsin deficiency is characterized by inadequate circulating levels of functional protein. Restoring its production could potentially provide a more direct therapeutic approach than replacing the protein through repeated treatment. However, reaching a proposed biochemical protective threshold does not independently establish that patients are protected against emphysema, progressive liver disease or other complications. Those outcomes require clinical evaluation over substantially longer periods.
Why does precise SERPINA1 gene correction matter for inherited lung and liver disease?
Alpha-1 antitrypsin deficiency is an inherited disorder primarily associated with mutations in the SERPINA1 gene, which provides instructions for producing alpha-1 antitrypsin. This protein is manufactured largely in the liver and circulates through the bloodstream, where it helps protect lung tissue against enzymes such as neutrophil elastase.
Patients with the severe PiZZ genotype produce an abnormal form of the protein known as Z-AAT. This form can accumulate within liver cells, while insufficient functional protein reaches the bloodstream to protect the lungs adequately. As a result, affected individuals may develop progressive lung damage, including emphysema, alongside liver inflammation, fibrosis or cirrhosis.
SERP-01 is designed to correct the disease-causing E342K mutation directly within liver cells. Its lipid nanoparticle formulation delivers messenger RNA encoding an adenine base editor together with a guide RNA that directs the editing machinery toward the targeted genetic sequence. Unlike conventional treatments that aim to increase circulating alpha-1 antitrypsin through repeated administration, SERP-01 seeks to restore endogenous production of the functional M-AAT protein.
The proposed advantage is that correcting the underlying mutation could potentially address both insufficient lung-protective protein and the production of abnormal protein associated with liver injury. Nevertheless, the ability to correct a genetic mutation does not automatically establish reversal of existing organ damage. SERP-01’s longer-term therapeutic effects remain unproven.
What did the liver biopsy and functional protein tests reveal about SERP-01’s mechanism?
One of the most notable findings came from a liver biopsy obtained 10 weeks after treatment from the participant receiving the 35 mg dose. DNA sequencing demonstrated 54% correction at the targeted genetic site, with no bystander editing detected at neighboring bases in the analyzed sample.
The finding provides direct evidence of target-site gene editing within human liver tissue, supporting the proposed mechanism of the treatment. Investigators also assessed the composition of circulating alpha-1 antitrypsin using liquid chromatography and mass spectrometry. By Week 3, the proportion identified as functional M-AAT reached 98.7% in the 35 mg participant and 93.4% in the 45 mg cohort.
The company noted that these measurements approached the upper analytical limits of the assay, making careful interpretation important. Functional testing provided further supporting evidence. An elastase inhibition assay performed one and two months after infusion showed that serum from three of four participants approached the activity observed in pooled healthy-donor samples.
All four participants demonstrated greater elastase inhibition activity than the PiZZ control serum, indicating that the treatment-associated protein changes were accompanied by measurable biological function. These observations strengthen the link between gene correction and the production of functional alpha-1 antitrypsin. However, the biopsy findings come from a single participant, and the absence of detected neighboring-base changes does not establish the absence of all possible off-target editing elsewhere in the genome.
How safe was the one-time SERP-01 gene-editing treatment in the early clinical study?
Serapha Bio reported no serious adverse events and no treatment-related adverse events of Grade 3 or higher among the four participants as of the data cutoff. These preliminary findings are encouraging for an investigational gene-editing treatment intended to produce potentially long-lasting biological changes after one administration.
However, the small patient population substantially limits conclusions about safety. Uncommon immune reactions, delayed complications, unintended genetic changes and longer-term consequences of treatment may not be detectable during early follow-up. Lipid nanoparticle delivery, immune responses to editing components and the accuracy of gene correction will require careful evaluation as the number of treated patients increases.
The reported results also do not establish that SERP-01 is safer than currently available treatment approaches, because the investigator-initiated study lacks a randomized comparison group. Future studies must establish not only whether functional protein levels remain elevated but also whether the treatment produces an acceptable balance between potential long-term benefits and the risks of permanent genetic modification.
How could SERP-01 differ from existing alpha-1 antitrypsin deficiency treatments?
Current management of alpha-1 antitrypsin deficiency includes smoking avoidance, appropriate respiratory care, treatment of associated complications and, for eligible patients, intravenous alpha-1 antitrypsin augmentation therapy. Augmentation therapy supplies functional protein but generally requires repeated administration and does not directly correct the inherited SERPINA1 mutation.
A successful one-time gene-editing therapy could potentially reduce the need for lifelong protein replacement while offering an approach directed at the molecular cause of the disease. The possibility of reducing abnormal Z-AAT production within the liver is also important because conventional augmentation treatment is directed toward lung protection rather than correcting the genetic mechanism responsible for liver protein accumulation.
However, the available SERP-01 results do not yet demonstrate improved lung function, reduced emphysema progression, reversal of liver fibrosis or avoidance of augmentation therapy. These clinical questions will determine whether the treatment’s promising biochemical effects translate into meaningful improvements in patient outcomes.
What comes next as Serapha Bio prepares a U.S. Phase 2/3 gene-editing trial?
Serapha Bio is preparing to initiate a U.S. Phase 2/3 study of SERP-01 in patients with PiZZ alpha-1 antitrypsin deficiency during late 2026 or early 2027. The U.S. Food and Drug Administration has cleared the Investigational New Drug application for the planned study and granted SERP-01 orphan drug and Regenerative Medicine Advanced Therapy designations.
These regulatory milestones support continued clinical development but do not constitute treatment approval or guarantee a favorable regulatory outcome. Serapha Bio holds exclusive development and commercialization rights outside Greater China through a licensing agreement with YolTech Therapeutics, the original developer of YOLT-202.
The company is also pursuing a proposed merger with Boundless Bio, a transaction that remains subject to shareholder and other closing conditions. The proposed combination does not change the preliminary nature of the clinical findings or establish the effectiveness of SERP-01. Future studies will need to confirm the durability of protein production, assess off-target editing and monitor clinical outcomes involving lung and liver health.
For patients with severe alpha-1 antitrypsin deficiency, the early results provide encouraging evidence that precise genetic correction may restore production of functional protein after a single infusion. The decisive question is whether these molecular and biochemical improvements can produce lasting clinical benefits without unacceptable long-term risks.
